摩根大通：2025 年全球中国医疗保健行业峰会--第一天会议要点

Investment Rating - The report maintains an "Overweight" (OW) rating for several companies, including Kelun Biotech, WuXi XDC, and Gushengtang, with specific price targets set for each [18][20][22]. Core Insights - Kelun Biotech is expected to have significant data readouts for its TROP2 ADC, with management confident in SKB264's potential as a leading drug. The company is also exploring AI's role in drug discovery, acknowledging its current limitations [3]. - Pharmaron and WuXi XDC show resilience against tariff impacts, with Pharmaron maintaining its FY25 guidance and WuXi XDC expecting minimal cost impacts from tariffs. WuXi XDC aims for 20% of its revenue from commercial projects by 2030 [3]. - AK Medical anticipates a 10-15% CAGR in the orthopedics consumable industry in China and expects mild price cuts during the upcoming VBP renewal, while projecting over 30% sales growth from overseas markets [3]. - Hutchmed is focusing on the sales growth of fruquintinib and sovalitinib, with expected approvals in China for new indications by 2025 and 2026, respectively [4]. - Gushengtang projects 25% revenue growth and 20% adjusted profit growth in FY25, leveraging its self-pay services to mitigate VBP pressures [4]. Summary by Company Kelun Biotech - Expected to present multiple data readouts in 2025, with confidence in SKB264 as a best-in-class drug. AI's role in drug discovery is acknowledged but seen as needing further development [3]. Pharmaron - Maintains FY25 guidance despite geopolitical uncertainties, indicating minimal impact from tariffs due to its service-heavy business model [3]. WuXi XDC - Projects 20% revenue from commercial projects by 2030 and minimal impact from tariffs, with a new Singapore site expected to start operations by the end of 2025 [3]. AK Medical - Expects the orthopedics consumable market to grow at 10-15% CAGR and anticipates mild price cuts during the VBP renewal, with significant overseas sales growth projected [3]. Hutchmed - Focused on fruquintinib and sovalitinib, with expected sales growth and new approvals in China for additional indications [4]. Gushengtang - Projects strong revenue and profit growth, leveraging self-pay services to reduce the impact of VBP pressures [4].